All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Tuberculosis (TB) remains an important health problem in several regions of the world, especially in countries with a high prevalence of HIV infection. *Mycobacterium tuberculosis* complex (MTBC) includes closely related species among which *M*. *tuberculosis*, *M*. *bovis*, and *M*. *africanum* are the most frequently associated with human disease. \[[@pntd.0004124.ref001]\] Unlike *M*. *tuberculosis*, *M*. *bovis* can infect a broad range of mammals, including cattle and, therefore, it is considered a zoonosis. The main mechanism of contagion in humans is the consumption of unpasteurized dairy products and, less frequently, animal-to-human and human-to-human contact. \[[@pntd.0004124.ref002]--[@pntd.0004124.ref004]\]

Historically, the burden of human TB caused by *M*. *bovis* (HTBMb) has been closely related to that of bovine TB (BTB) in the same region.\[[@pntd.0004124.ref005]\] Unfortunately, data from most developing countries, where there is still inappropriate BTB control, is scarce.\[[@pntd.0004124.ref006],[@pntd.0004124.ref007]\] There are several factors that explain the underreporting of HTBMb in these regions. First, control programs rely on acid-fast bacilli (AFB) smears as the primary diagnostic method in suspected TB cases; and mycobacterial culture is performed only when drug resistance is suspected, or treatment is failing. Second, most laboratories use culture medium containing glycerol, and this reduces the probability of *M*. *bovis* isolation. Lastly, only a few laboratories can identify MTBC at the species level.\[[@pntd.0004124.ref008],[@pntd.0004124.ref009]\] In Mexico, one national reference laboratory (Instituto Nacional de Diagnóstico y Referencia Epidemiológicos) and 32 public health laboratories are capable of performing mycobacterial cultures. However, species-level identification is not routinely performed. Consequently, data regarding first-line anti-tuberculosis drug susceptibility for MBTC are scarce. Therefore, describing the burden of HTBMb and first-line drug susceptibility pattern has important implications for treatment, referral, and public health policies in developing countries. We describe the trends of *M*. *bovis* isolation and first-line drug susceptibility for a referral laboratory in a tertiary care hospital during a 15-year period.

Methods {#sec005}
=======

This study was conducted at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, one of the National Institutes of Health in Mexico. This tertiary care referral center accepts adult patients from all over the country. The patient population involves complex medical and surgical cases including rheumatologic patients, bone marrow and solid organ transplant recipients, and HIV patients. The Laboratory of Clinical Microbiology receives local and referred clinical samples from other National Institutes of Health as well as other hospitals in Mexico City and nearby states for mycobacterial culture. Since 1992, as a regular practice, samples from patients suspected to have TB undergo mycobacterial culture, species-level identification and first-line drug susceptibility testing in all instances. We selected the 2000--2014 period because laboratory practices for mycobacterial isolation, identification, and susceptibility testing became more uniform then.

Ethics statement {#sec006}
----------------

Institutional approval for this study was obtained from the Comité Institucional de Investigación Biomédica en Humanos. All data analyzed were anonymized.

Data collection and definitions {#sec007}
-------------------------------

A search was performed using the Laboratory of Clinical Microbiology database to investigate all MTBC isolates from January 2000 to December 2014. This database includes both local and referred samples. Only the first isolate was considered for the analysis when multiple samples within a 6-month period were available for a single patient. Whenever there were additional isolates from the same patient ≥ 6 months apart, they were considered as separate episodes and included for analysis.

Data on mycobacterial species, drug susceptibility, sample source, treatment, and referral status were obtained. HIV status was obtained for local samples only. Primary resistance (new cases) was defined as those samples from patients without previous anti-tuberculosis treatment. Secondary resistance (treated cases) was defined as those samples from patients who had previously received any anti-tuberculosis treatment. Resistance to both isoniazid (INH) and rifampin (RIF) was defined as multidrug resistance (MDR). Polydrug resistance was defined as resistance to two or more drugs but excluding those classified as MDR. Samples from sputum, bronchoalveolar lavage, endotracheal aspirate, gastric aspirate, lung and pleural biopsy, and pleural fluid were classified as pulmonary. Liver, spleen, and gastrointestinal biopsies, as well as ascites fluid, and fecal samples were classified as abdominal. Additionally, if samples from the same patient were obtained from a pulmonary and an extrapulmonary source, the case was classified as pulmonary.

Microbiology procedures {#sec008}
-----------------------

As a laboratory standard procedure, all samples obtained from bronchoalveolar lavage, cerebrospinal fluid, and biopsies from any tissue or abscess were cultured in mycobacteria-specific culture medium, regardless of TB suspicion. Sputum and urine samples were cultured for mycobacteria at the request of the treating physician.

Samples were digested and decontaminated by the NALC-NaOH method as previously described. \[[@pntd.0004124.ref010],[@pntd.0004124.ref011]\] After digestion, samples were inoculated in both Löwenstein-Jensen medium and MGIT tubes (Becton-Dickinson, Sparks, MA, USA) according to the manufacturer's specifications. Biopsy samples were additionally inoculated in Stonebrink culture medium. Additionally, smears from all samples were prepared for Ziehl-Neelsen and Auramine-rhodamine stain. Isolates obtained from MGIT tubes were sub-cultured in Stonebrink and Löwenstein-Jensen medium. All positive cultures were further identified by DNA probe (Accuprobe, GEN-PROBE, San Diego, CA). Biochemical tests (niacin production, nitrate reduction, thiophen-2-carboxylic acid anhydride susceptibility, and pyrazinamidase deamidation) for the identification of *M*. *bovis* were performed in those positive cultures with dysgonic growth. \[[@pntd.0004124.ref012]\] Spoligotyping was performed for local isolates as previously described, and data was entered into an international database ([www.mbovis.org](http://www.mbovis.org)).\[[@pntd.0004124.ref013]\] Susceptibility testing for anti-tuberculosis drugs was performed for INH, RIF, streptomycin (STR) and ethambutol (EMB). For this purpose, and according to the manufacturer's specifications, the radiometric BACTEC 460 TB culture system (Becton-Dickinson, Sparks, MA, USA) was used from the years 2000 to 2010 with the following drug concentrations: INH (0.1 μg/mL), RIF (2.0 μg/mL), EMB (7.5 μg/mL), and STR (6.0 μg/mL); then, from 2010 on, the BACTEC MGIT 960 culture system (Becton-Dickinson, Sparks, MA, USA) was used with the following concentrations: INH (0.1 μg/mL), RIF (1.0 μg/mL), EMB (5.0 μg/mL), STR (2.0 μg/mL). This laboratory is subjected to regular quality control evaluations by the Centers for Disease Control and Prevention, and the College of American Pathologists for identification and susceptibility testing of mycobacteria species.

Statistical analysis {#sec009}
--------------------

Statistical analysis was performed using STATA 11.0 software (StataCorp, College Station, TX, USA). Categorical data was summarized using frequency tables, and the X^2^ test was used for comparison between groups. The *M*. *bovis* case proportion by year was analyzed obtaining a X^2^ for trend by the Armitage test (regression). A p-value \<0.05 was determined as statistically significant for all tests.

Results {#sec010}
=======

Mycobacterial species and patient characteristics {#sec011}
-------------------------------------------------

During the study period, 81,521 samples were processed for mycobacterial culture ([Fig 1](#pntd.0004124.g001){ref-type="fig"}). Among these, 1,165 MTBC isolates were identified, 583 (50.0%) as local samples and 582 (49.9%) as referrals after eliminating duplicate cultures. Of these, 73.7% (859/1,165) were identified as *M*. *tuberculosis*, and 26.2% (306/1,165) as *M*. *bovis*. Sixty-two percent of the *M*. *tuberculosis* isolates and 35.2% of the *M*. *bovis* isolates were obtained from pulmonary samples (p\<0.001; [Table 1](#pntd.0004124.t001){ref-type="table"}). Data on AFB stain were available for 954 isolates; the proportion of positive AFB stain was 75.9% (378/680) for *M*. *tuberculosis*, and 24.1% (120/274) for *M*. *bovis* (p = 0.001). Among the AFB-positive *M*. *bovis* isolates, 45.8% (55/120) were pulmonary, and 54.1% (65/120) were extrapulmonary (p = 0.018). Conversely, among the AFB-positive *M*. *tuberculosis* isolates, 79.3% (300/378) were pulmonary and 20.6% (78/378) were extrapulmonary (p\<0.001).

![Samples processed for mycobacterial culture during the study period.](pntd.0004124.g001){#pntd.0004124.g001}

10.1371/journal.pntd.0004124.t001

###### Anatomical Site of Isolation.

![](pntd.0004124.t001){#pntd.0004124.t001g}

  Site                                              Total (N = 1,165)   *M*. *tuberculosis* (n = 859)   *M*. *bovis* (n = 306)   p[\*](#t001fn002){ref-type="table-fn"}
  ------------------------------------------------- ------------------- ------------------------------- ------------------------ ----------------------------------------
  Pulmonary[^1^](#t001fn003){ref-type="table-fn"}   647(55.5)           539 (62.7)                      108 (35.3)               \<0.001
  Bone, joint, skin, and soft-tissue                51 (4.4)            35 (4.1)                        16 (5.2)                 0.397
  Genitourinary                                     73 (6.3)            51 (5.9)                        22 (7.2)                 0.438
  Blood or bone marrow                              39 (3.3)            34 (4)                          5 (1.6)                  0.052
  Cerebrospinal fluid                               95 (8.2)            58 (6.8)                        37 (12.1)                0.003
  Abdominal[^2^](#t001fn004){ref-type="table-fn"}   55 (4.7)            26 (3)                          29 (9.5)                 \<0.001
  Lymph node                                        138 (11.8)          78 (9.1)                        60 (19.6)                \<0.001
  Other                                             67 (5.8)            38 (4.4)                        29 (9.5)                 0.001
  Total extrapulmonary                              518 (44.4)          320 (37.2)                      198 (64.7)               \<0.001

NOTE.

\* X^2^ test.

^1^ Sputum, bronchoalveolar lavage, endotracheal aspirate, gastric aspirate, lung and pleural biopsy, and pleural fluid.

^2^ Liver, spleen, and gastrointestinal biopsies, ascites fluid, and fecal samples.

One hundred and twelve (19.2%) local isolates were from HIV-infected patients; 63.3% (71/112) were *M*. *tuberculosis*, and 36.6% (41/112) were *M*. *bovis* (p = 0.054). Among the samples from HIV-infected patients, 52.6% (59/112) were pulmonary samples. Of these, 76.2% (45/59) were identified as *M*. *tuberculosis*, and 23.7% (14/59) were *M*. *bovis*.

The overall proportion of *M*. *bovis* isolation significantly increased from 7.8% in 2000 to 28.4% in 2014 (*X* ^*2*^ ~trend~, p\<0.001; [Fig 2](#pntd.0004124.g002){ref-type="fig"}). Spoligotype pattern was available for 63.5% (108/170) of the local samples ([S1 Table](#pntd.0004124.s001){ref-type="supplementary-material"}).

![*Mycobacterium tuberculosis* complex Isolates per year and *M*. *bovis* proportions.](pntd.0004124.g002){#pntd.0004124.g002}

Susceptibility to first-line anti-tuberculosis drugs {#sec012}
----------------------------------------------------

Data on first-line anti-tuberculosis drugs susceptibility were available for 1,139 (97.7%) isolates ([Table 2](#pntd.0004124.t002){ref-type="table"}). When considering monoresistance among all isolates, 10.9% of *M*. *bovis* and 3.2% of *M*. *tuberculosis* were resistant to STR (p\<0.001). This association remained after stratifying by new and treated cases (p\<0.001 and p = 0.032, respectively). Total MDR among all cases was 11.9% for *M*. *tuberculosis* and 7.6% for *M*. *bovis* (p = 0.038). This same association was observed among new cases (6.8% vs. 3%, p = 0.026). However, among treated cases no difference was observed.

10.1371/journal.pntd.0004124.t002

###### First-line drug resistance profile.

![](pntd.0004124.t002){#pntd.0004124.t002g}

                                            All cases n (%)                                          Primary resistance (New cases) n (%)                                          Secondary resistance (Treated cases) n (%)               
  ---------------------------- ------------ ----------------- ----------- ------------- ------------ -------------------------------------- ----------- ------------- ------------ -------------------------------------------- ----------- -----------
  Any drug resistance                                                                                                                                                                                                                       
  INH                          228 (20)     179 (21.4)        49 (16.1)   **0.047**     135 (14.3)   104 (15.3)                             31 (11.7)   0.158         93 (48.2)    75 (48.7)                                    18 (46.2)   0.776
  RIF                          143 (12.6)   114 (13.7)        29 (9.5)    0.064         72 (7.6)     58 (8.5)                               14 (5.3)    0.092         71 (36.8)    56 (36.4)                                    15 (38.5)   0.808
  EMB                          27 (2.4)     25 (3)            2 (0.7)     **0.022**     14 (1.5)     13 (1.9)                               1 (0.4)     0.080         13 (6.7)     12 (7.8)                                     1 (2.6)     0.245
  STR                          120 (10.5)   84 (10.1)         36 (11.8)   0.386         90 (9.5)     59 (8.7)                               31 (11.7)   0.153         30 (15.5)    25 (16.2)                                    5 (12.8)    0.599
  Total any drug resistance    309 (27.1)   221 (26.5)        88 (28.9)   0.405         205 (21.7)   139 (20.4)                             66 (24.9)   0.132         104 (53.9)   82 (53.2)                                    22 (56.4)   0.723
  Monoresistance                                                                                                                                                                                                                            
  INH                          77 (6.8)     54 (6.5)          23 (7.6)    0.514         57 (6)       36 (5.3)                               21 (7.9)    0.126         20 (10.4)    18 (11.7)                                    2 (5.1)     0.230
  RIF                          19 (1.7)     13 (1.6)          6 (2)       0.627         16 (1.7)     10 (1.5)                               6 (2.3)     0.394         3 (1.6)      3 (1.9)                                      0 (0)       \--
  EMB                          \--          \--               \--         \--           \--          \--                                    \--         \--           \--          \--                                          \--         \--
  STR                          60 (5.3)     27 (3.2)          33 (10.9)   **\<0.001**   52 (5.5)     23 (3.4)                               29 (10.9)   **\<0.001**   8 (4.1)      4 (2.6)                                      4 (10.3)    **0.032**
  Total monoresistance         156 (13.7)   94 (11.3)         62 (20.4)   **\<0.001**   125 (13.2)   69 (10.1)                              56 (21.1)   **\<0.001**   31 (16.1)    25 (16.2)                                    6 (15.4)    0.897
  Multidrug resistance                                                                                                                                                                                                                      
  INH+RIF                      76 (6.6)     55 (6.5)          21 (6.9)    0.848         34 (3.5)     27 (3.9)                               7 (2.6)     0.326         42 (21.7)    28 (18.1)                                    14 (35.9)   **0.017**
  INH+RIF+EMB                  15 (1.3)     13 (1.6)          2 (0.7)     0.239         6 (0.6)      5 (0.7)                                1 (0.4)     0.535         9 (4.7)      8 (5.2)                                      1 (2.6)     0.486
  INH+RIF+STR                  24 (2.1)     24 (2.9)          0 (0)       \--           10 (1.1)     10 (1.5)                               0 (0)       \--           14 (7.3)     14 (9.1)                                     0 (0)       \--
  INH+RIF+EMB+STR              7 (0.6)      7 (0.8)           0 (0)       \--           4 (0.4)      4 (0.6)                                0 (0)       \--           3 (1.6)      3 (1.9)                                      0 (0)       \--
  Total multidrug resistance   122 (10.7)   99 (11.9)         23 (7.6)    **0.038**     54 (5.7)     46 (6.8)                               8 (3)       **0.026**     68 (35.2)    53 (34.4)                                    15 (38.5)   0.637
  Polydrug resistance                                                                                                                                                                                                                       
  INH+EMB                      2 (0.2)      2 (0.2)           0 (0)       \--           2 (0.2)      2 (0.3)                                0 (0)       \--           0 (0)        0 (0)                                        0 (0)       \--
  INH+STR                      25 (2.2)     22 (2.6)          3 (1)       0.093         21 (2.2)     19 (2.8)                               2 (0.8)     0.056         4 (2.1)      3 (1.9)                                      1 (2.6)     0.809
  RIF+STR                      1 (0.1)      1 (0.1)           0 (0)       \--           1 (0.1)      1 (0.1)                                0 (0)       \--           0 (0)        0 (0)                                        0 (0)       \--
  RIF+EMB+STR                  1 (0.1)      1 (0.1)           0 (0)       \--           1 (0.1)      1 (0.1)                                0 (0)       \--           0 (0)        0 (0)                                        0 (0)       \--
  Total polydrug resistance    31 (2.7)     28 (3.4)          3 (1)       **0.03**      26 (2.7)     24 (3.5)                               2 (0.8)     **0.019**     5 (2.6)      4 (2.6)                                      1 (2.6)     0.991

NOTE.

\* X^2^ test. INH.---Isoniazid; RIF.-. Rifampin; EMB.---Ethambutol; STR.--Streptomycin.

An increasing trend of STR monoresistance among new cases was found when considering both species (3.4% in 2000--2004 vs. 7.6% in 2010--2014, p = 0.02) ([Table 3](#pntd.0004124.t003){ref-type="table"}).

10.1371/journal.pntd.0004124.t003

###### Primary resistance trends of *Mycobacterium tuberculosis* complex across time.

![](pntd.0004124.t003){#pntd.0004124.t003g}

                                      Total %                             *M*. *tuberculosis* %                         *M*. *bovis* %          
  ---------------------------- ------ --------- ------ ----------- ------ ----------------------- ------ ------- ------ ---------------- ------ -------
  No. isolates tested          258    335       353                213    238                     230            45     97               123    
  Drug resistance pattern                                                                                                                       
  Any drug resistance                                                                                                                           
  Any resistance to INH        10.1   16.2      10.4   0.874       10.9   17.1                    11.2   0.963   6.3    14.2             8.9    0.977
  Any resistance to RIF        4.1    10.7      5.6    0.690       4.5    12.2                    6.1    0.573   2.2    6.7              4.7    0.755
  Any resistance to EMB        0.8    2.0       1.4    0.595       0.9    2.9                     1.7    0.567   0      0                0.8    0.341
  Any resistance to STR        6.2    8.0       11.1   **0.023**   6.2    7.4                     10.2   0.103   6.3    9.3              12.8   0.174
  Total any drug resistance    13.4   20.2      18.5   0.119       13.4   19.9                    17.0   0.308   13.5   21.1             21.2   0.320
  Monoresistance                                                                                                                                
  Monoresistance to INH        4.8    6.4       5.6    0.713       4.5    5.6                     5.0    0.824   6.3    8.5              6.8    0.959
  Monoresistance to RIF        0.8    1.8       2.2    0.172       0.5    2.1                     1.7    0.283   2.2    1.0              3.1    0.501
  Monoresistance to STR        3.4    4.0       7.6    **0.012**   2.7    2.1                     5.0    0.169   6.3    8.5              12.1   0.191
  Total monoresistance         8.5    11.4      14.1   **0.023**   7.4    9.2                     10.9   0.187   13.5   16.4             19.6   0.281
  Multidrug resistance                                                                                                                          
  INH+RIF                      2.3    6.9       1.4    0.333       2.8    7.1                     1.7    0.514   0      6.2              0.8    0.583
  INH+RIF+EMB                  0.4    0.9       0.6    0.839       0.5    1.2                     0.4    0.945   0      0                0.8    0.341
  INH+RIF+STR                  0.8    1.5       0.8    0.999       0.9    2.1                     1.3    0.770   0      0                0      \--
  INH+RIF+EMB+STR              0      0.9       0.3    0.708       0      1.2                     0.4    0.577   0      0                0      \--
  Total Multidrug resistance   3.4    9.2       3.0    0.566       4.1    10.5                    3.8    0.837   0      5.8              1.6    0.866

NOTE.

\* X^2^ test for trend. INH.---Isoniazid; RIF.-. Rifampin; EMB.---Ethambutol; STR.--Streptomycin.

Discussion {#sec013}
==========

This report demonstrates a high prevalence and a rising trend in the proportion of *M*. *bovis* isolation in our laboratory. This report is one of the largest on first-line anti-tuberculosis drug profile of *M*. *bovis* and shows a noteworthy proportion of first-line anti-tuberculosis drug resistance and secondary MDR isolates.

The proportion of *M*. *bovis* isolates in this study (26.2%) is much higher than that reported by other hospital-based studies in Latin America (0.4%) and by other hospitals in Mexico (\<1%). \[[@pntd.0004124.ref014],[@pntd.0004124.ref015]\] This may be explained by the larger study period of the present report and the high proportion of samples from immunosuppressed patients who are at a greater risk for *M*. *bovis* infection, as documented in previous studies.\[[@pntd.0004124.ref016]\] In fact, isolates obtained from HIV-infected patients accounted for 19.2% of the local samples.\[[@pntd.0004124.ref017]\]

We also identified a rising trend in the proportion of cases caused by *M*. *bovis* across time. HMBTb is considered a reflection of the BTB burden in the region. In fact, we recently identified a high burden of bovine and human TB in a dairy production facility in rural Mexico. \[[@pntd.0004124.ref002]\] This also correlates with previous reports of *M*. *bovis* among artisanal dairy products, which have been linked to HMBTb cases in Mexico and along the south border cities of the United States.\[[@pntd.0004124.ref018],[@pntd.0004124.ref019]\] Mexico is considered a country of "sporadic occurrence" of BTB by the World Organization for Animal Health. However, like in many countries in the region, the test-and-slaughter strategy for bovine tuberculosis control is not universally implemented. \[[@pntd.0004124.ref006]\] The main obstacles for BTB control in Mexico are financial and cultural. Official government data reports an overall prevalence of BTB of 2.05% in 2015, but it reaches 16.5% among dairy farms.\[[@pntd.0004124.ref020]\] The reason for this difference may be explained by the fact that meat producing regions require to be certified as BTB free for cattle export. On the contrary, in dairy production farms, BTB only mildly affects production and pasteurization eliminates *M*. *bovis*. \[[@pntd.0004124.ref021]\] Unfortunately, about 30% of the milk production in Mexico is sold without pasteurization, mostly to small retailers and artisan cheese producers.\[[@pntd.0004124.ref022]\]

The respiratory route of contagion is considered less efficient for *M*. *bovis* than for *M*. *tuberculosis*. However, recent data detailing outbreaks in the community and hospitals demonstrated that human-to-human contagion is not as unlikely as previously believed.\[[@pntd.0004124.ref003],[@pntd.0004124.ref023],[@pntd.0004124.ref024]\] Interestingly, we observed an important proportion (16.6%) of *M*. *bovis* isolates recovered from pulmonary samples from a mainly urban population. Therefore, it may be hypothesized that airborne human-to-human transmission of *M*. *bovis* may occur in the community, but remains undetected in our region given that mycobacterial culture is not routinely performed. Unfortunately, as an important limitation of this study, the lack of clinical and epidemiologic data precludes us from reaching a definite conclusion.

We also report a high rate of first-line anti-tuberculosis resistance for MBTC. The proportion of INH (14%), RIF (7.6%), and STR (5.5%) primary resistance found among new cases is considerably higher for INH and RIF than in previous reports from our group in 1995 (INH 6%, RIF 2%, STR 6%).\[[@pntd.0004124.ref025]\] These proportions are also higher than those from other reports in Mexico (1995 to 2006) among new cases (INH 9%, RIF 3%, and MDR 4.5%), and are also higher than recent data from the National Survey on TB Drug Resistance in Mexico (INH 3.5%, RIF 0.1%, STR 4% and MDR 2.3%).\[[@pntd.0004124.ref026],[@pntd.0004124.ref027]\] This discrepancy may be explained by the different periods from which data was collected and the dissimilar patient population (ours being hospital-based and including more HIV-infected, and immunosuppressed patients).

When comparing the resistance profiles of *M*. *bovis* and *M*. *tuberculosis*, we observed a considerably higher primary MDR *M*. *tuberculosis* proportion, and a significantly higher STR monoresistance among *M*. *bovis* isolates. Data regarding drug susceptibility for *M*. *bovis* TB in humans and animals is limited. A study from San Diego reported 7% resistance for INH and 1% for RIF among 167 *M*. *bovis* TB cases.\[[@pntd.0004124.ref028]\] Drug susceptibility has also been reported from outbreaks caused by MDR strains; however, most other case series of HTBMb report full susceptibility to all first-line anti-tuberculosis drugs.\[[@pntd.0004124.ref014],[@pntd.0004124.ref015],[@pntd.0004124.ref029]--[@pntd.0004124.ref032]\] A report from the National TB Genotyping Service of the United States informed of 17% of STR resistance among 165 *M*. *bovis* isolates; however, no explanation for this was proposed. \[[@pntd.0004124.ref033]\] Drug susceptibility from *M*. *bovis* isolates collected from farm animals or wildlife is almost uniformly reported as fully susceptible to anti-tuberculosis drugs.\[[@pntd.0004124.ref034]--[@pntd.0004124.ref036]\]. We believe that a high proportion of primary resistance for STR among *M*. *bovis* isolates, may be explained by the use of aminoglycosides for treating other diseases in cattle.\[[@pntd.0004124.ref037]\] Some have suggested that primary resistance to INH and RIF in *M*. *bovis* may indicate human-to-human transmission.\[[@pntd.0004124.ref032]\] However, we surveyed BTB in a dairy farm, where samples from cows were obtained during necropsy. We recovered 150 *M*. *bovis* isolates; among these, we observed an even higher rate of STR resistance (15.6%) and a similar rate of INH (9.2%) and RIF (3.4%) resistance. (M. Bobadilla, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, personal communication).

It has been suggested that HTBMb cases may be at a higher risk for developing MDR strains if natural resistance to pyrazinamide is not considered and monoresistance to INH or RIF is present. \[[@pntd.0004124.ref038],[@pntd.0004124.ref039]\] We identified a similar proportion of secondary MDR *M*. *bovis* and *M*. *tuberculosis* isolates. Unfortunately, only a few cases were analyzed and no data on previous treatments or outcomes were available, therefore we are unable to conclude if this assumption is true. Nevertheless, it should be recognized that TB cases caused by MDR *M*. *bovis* may result in disease that is harder to treat on a second- line drug regimen. This highlights the need for performing species-level identification and drug susceptibility testing whenever *M*. *bovis* is suspected.

In conclusion, we believe that data contained in this study is relevant in terms of public health and highlights the need for more stringent control of BTB in our country. It also underscores the importance of proper identification of *M*. *bovis* given that the considerable rate of primary resistance to INH and RIF along with the natural pyrazinamide resistance may result in treatment failures and select for MDR strains.
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